


# NCAB ad hoc subcommittee

Presentation by  
Dr. Ted Trimble  
March 23, 2016


# Global Cancer Trends (IARC)

## Human Development Index (2008-2030)



- **Highest HDI:** Breast, lung, colorectum, prostate cancers (over 50%)
- **Medium HDI:** Add esophagus, stomach, liver; **Low HDI:** cervical cancer

# Non-Communicable Disease Burden is Increasing Worldwide



Major NCDs: Cardiovascular disease, cancer, chronic lung disease, diabetes

Data: Global Burden of Disease Study 2010

(Lancet. Vol 380 Dec 15/22/29, 2012 – [www.healthmetricsandevaluation.org](http://www.healthmetricsandevaluation.org))

# NCI's Global Priorities

- Support Cancer Research Globally
- Train International Scientists
- Engage in Cancer Control Planning

# CGH Priorities in Global Health


- Strengthening global cancer research
- Building a global cancer research community
- Translating research results into practice

## History of CGH

- Announced in 2011 by Dr. Varmus
- Intention to serve as focal point for NCI Global activities
- Merged personnel and budget from
  - Office of International Affairs
  - Office of Latin America Cancer Program Development
  - Liaison Office (Brussels)
  - China Cancer Office

# OD Budget (including research grants)

Total Budget: \$1.5B



# Specific Programmatic Highlights

- Development of a CGH research Program
- Deep Dive: Kenya
- Networks: Burkitt Lymphoma as an example



# Development of Research Program


## Concept development to FOA CGH leads:

- RFP NCI-Designated Cancer Center Supplements ('13)
- PAR 15 155 NCI designated cancer centers P 30 supplements for global health research
- RFA 15 007: NCD Regional centers for research excellence
- PA 16 086 NCI designated cancer centers P 30 supplements for Burkitt's Lymphoma pilot projects

## Co-development with other divisions and centers:

- K 43 career development award for global health research (FIC)
- K 01 career development award for global health research (FIC)
- R 21 NCD across the lifespan (FIC)
- UH02/03 low cost technology coordinated by CGH, multiple divisions
-

# NCI-Designated Cancer Centers – African Projects



# Joining forces to overcome cancer: The Kenya cancer research and control stakeholder program

Read more about NCI's work in Kenya: *Joining forces to overcome cancer: The Kenya cancer research and control stakeholder program*

<http://www.sciencedirect.com/science/article/pii/S2213538315300138>.

## Initial 2016 Evaluation

### Highlights

- **67%** respondents reported increased interactions with Ministry of Health;
- Kenyan Government has funded **5** new cancer registry staff to match NCI funds;
- **33%** of respondents reported they were able to better leverage USG investments in Kenya;
- **33%** of respondents reported submission of grant applications and development of regional research networks

**2013:** NCI's portfolio analysis

**2014:** National Cancer Stakeholder Meeting

**2014:** NCI Leadership Forum in Cancer Control planning

**2015:** Quality and needs assessment task force

**2015:** Coordination of activities in partnership with ACS, MOH and partners.

**2015:** CGH received 3 RCRE applications

**2015-2016:** Phase II meetings for Research and Community Education

**2015-2016:** Kenya establishes specific technical working groups

**2016:** Funding for pathology strengthening

**2016:** Second consultant placed in Kenya for 2016-2017.

**2016:** Technical Support in evaluation of the National Cancer Control Strategy

**2016:** WE-CAN meeting in April 2016,

**2016:** MOU between NCI-Kenya and US NCI to facilitate future research collaboration.

# Burkitt Lymphoma Research Network

- **P30 supplements** (June 2016)
  - 7-10 LMIC centers \$100K x 2 yrs
- **U01** (2018) supporting the network

## Research Projects for Burkitt Lymphoma Research Network

1. **Implementation Science project** – Develop resource-appropriate diagnostic and treatment platforms
2. **Biology of regional associated cancer** – comparison of molecular biology/genomics of Burkitt lymphoma - endemic (Africa vs. Latin America) vs. EBV(-) vs. HIV associated
3. **Precision Cancer Prevention** – Africa in optimal platform to test potential EBV vaccines

# Questions?

## CGH Contact Information

**Website:**

[www.cancer.gov/globalhealth](http://www.cancer.gov/globalhealth)

**Telephone number:**

+1-240-276-5810

**Office street address:**

9609 Medical Center Drive, Rockville, MD  
(near Shady Grove Adventist Hospital)

**Email:**

[NCIGlobalHealth@mail.nih.gov](mailto:NCIGlobalHealth@mail.nih.gov)

**Twitter Handle:**

@NCIGlobalHealth

**GCPM:**

[www.gcpm.globalonc.org](http://www.gcpm.globalonc.org)

